Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698822 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
A Phase 2 study of Cutaneous T Cell Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06698822 is a Phase 2 study of Cutaneous T Cell Lymphoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06698822, a Phase 2 study of Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.
Conditions Studied
Interventions
- DRUG tofacitinib 2% cream
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698822
The ClinicalTrials.gov registry entry for NCT06698822 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which tofacitinib 2% cream is the first listed.
NCT06698822 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06698822 about?
NCT06698822 is a clinical study titled "A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA". To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.
What is the current status of trial NCT06698822?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-03-10. Estimated completion is 2026-10-19.
What conditions does trial NCT06698822 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.
What interventions are being tested in trial NCT06698822?
The interventions under investigation include: tofacitinib 2% cream (DRUG).
Who is sponsoring clinical trial NCT06698822?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06698822 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
RECRUITING · Phase 2
-
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
COMPLETED · Phase 2
-
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
COMPLETED · Phase 2
-
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.